Combined Proteasome and Autophagy Inhibition in Relapsed/Refractory Multiple Myeloma-A Phase I Trial of Hydroxychloroquine, Carfilzomib, and Dexamethasone.
Tobias S Slørdahl, Frida Bugge Askeland, Margrete Sofie Sætre Hanssen, Håkon Hov, Stine Marie Sundt-Hansen, Sofia Lindahl, Nils Tore Vethe, Henrik Hjorth-Hansen, Mona H Fenstad, Anders Waage, Øyvind Hjertner, Fredrik Schjesvold, Anders Sundan
{"title":"Combined Proteasome and Autophagy Inhibition in Relapsed/Refractory Multiple Myeloma-A Phase I Trial of Hydroxychloroquine, Carfilzomib, and Dexamethasone.","authors":"Tobias S Slørdahl, Frida Bugge Askeland, Margrete Sofie Sætre Hanssen, Håkon Hov, Stine Marie Sundt-Hansen, Sofia Lindahl, Nils Tore Vethe, Henrik Hjorth-Hansen, Mona H Fenstad, Anders Waage, Øyvind Hjertner, Fredrik Schjesvold, Anders Sundan","doi":"10.1002/jha2.1091","DOIUrl":null,"url":null,"abstract":"<p><p>Multiple myeloma is characterized by malignant cells which produce high amounts of monoclonal immunoglobulin. Myeloma cells are, therefore, dependent on effective protein degradation. Proteasomal protein degradation is targeted by proteasome inhibitors in routine care. Autophagic protein degradation is currently not targeted in myeloma treatment. This Phase I trial showed that the combination of the proteasome inhibitor carfilzomib and the autophagy inhibitor hydroxychloroquine was well tolerated in patients with relapsed/refractory multiple myeloma. Adverse events were mostly Grades 1 and 2. An overall response rate of 44% indicates a meaningful clinical efficacy of this combination. <b>Trial Registration</b>: The study was registered at clinicaltrials.gov # NCT04163107.</p>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 1","pages":"e1091"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11756982/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/jha2.1091","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Multiple myeloma is characterized by malignant cells which produce high amounts of monoclonal immunoglobulin. Myeloma cells are, therefore, dependent on effective protein degradation. Proteasomal protein degradation is targeted by proteasome inhibitors in routine care. Autophagic protein degradation is currently not targeted in myeloma treatment. This Phase I trial showed that the combination of the proteasome inhibitor carfilzomib and the autophagy inhibitor hydroxychloroquine was well tolerated in patients with relapsed/refractory multiple myeloma. Adverse events were mostly Grades 1 and 2. An overall response rate of 44% indicates a meaningful clinical efficacy of this combination. Trial Registration: The study was registered at clinicaltrials.gov # NCT04163107.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
